ライフサイエンスコーパス: adverse drug reaction

1 h, disease remission or the occurrence of an adverse drug reaction.

2 ight into the pathophysiology of this severe adverse drug reaction.

3 determine interindividual susceptibility to adverse drug reactions.

4 to pharmacotherapy whereas others experience adverse drug reactions.

5 orphisms that may underlie susceptibility to adverse drug reactions.

6 global analysis linking chemical features to adverse drug reactions.

7 ten inhibited by variable drug responses and adverse drug reactions.

8 e II binding compounds is essential to avoid adverse drug reactions.

9 ug pharmacokinetics, treatment efficacy, and adverse drug reactions.

10 an skin, a common target of inflammation and adverse drug reactions.

11 ficacy and reduce the number and severity of adverse drug reactions.

12 ommunity and hospital nurses in reporting of adverse drug reactions.

13 T cells involved in other serious cutaneous adverse drug reactions.

14 wn but cannot account for most idiosyncratic adverse drug reactions.

15 ehensive information on the risks of serious adverse drug reactions.

16 IV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions.

17 o repurpose existing drugs and identify rare adverse drug reactions.

18 the organs most commonly involved in serious adverse drug reactions.

19 ntial for serious drug-drug interactions and adverse drug reactions.

20 ovigilance system was put in place to detect adverse drug reactions.

21 alanced considering the increased tremor and adverse drug reactions.

22 actam therapy without increasing the risk of adverse drug reactions.

23 et of covariates that influenced the rate of adverse drug reactions.

24 ajor, minor, and potentially iatrogenic; and adverse drug reactions.

25 by endocrine disrupting chemicals (EDCs) and adverse drug reactions.

26 marker studies advanced the understanding of adverse drug reactions.

27 ded details of 10 and 3 reports of suspected adverse drug reactions.

28 t in drug metabolism and have been linked to adverse drug reactions.

29 ase, resistance to pathogens and the risk of adverse drug reactions.

30 h need for additional drug therapy (31%) and adverse drug reactions (18%) being the most common probl

31 We recorded no serious adverse drug reactions; 28 adverse events, most commonly

32 < .001) without any increase in incidence of adverse drug reactions (4% vs 3%; P = .4).

33 and 1.7% for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.

34 Ritonavir was associated with adverse drug reactions about twice as frequently as indi

35 ISDs owing to clinical efficacy, inefficacy, adverse drug reaction (ADR), and other medical causes.

36 Adverse drug reactions (ADRs) accounted for the majority

37 Two spontaneously reported serious adverse drug reactions (ADRs) and 32 spontaneously repor

38 of studies identifying HLA associations with adverse drug reactions (ADRs) and one for the examinatio

39 Adverse drug reactions (ADRs) are a central consideratio

40 Adverse drug reactions (ADRs) are a relatively common ca

41 Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized sou

42 Adverse drug reactions (ADRs) are commonplace and occur

43 Idiosyncratic adverse drug reactions (ADRs) are one of the most common

44 aim of the study was to investigate whether adverse drug reactions (ADRs) during immunotherapy with

45 Adverse drug reactions (ADRs) pose critical public healt

46 rugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, bu

47 , spontaneous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separate

48 onvulsant carbamazepine 1 is associated with adverse drug reactions (ADRs), including hepatotoxicity;

49 A total of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstr

50 duct were classified by the investigators as adverse drug reactions (ADRs).

51 rgy to cephalosporin or incidence of serious adverse drug reactions (ADRs).

52 ontinue thiopurine therapy because of severe adverse drug reactions (ADRs); leukopenia is one of the

53 to clarify key terms, such as adverse event, adverse drug reaction, adverse drug event, medication er

54 d serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) fo

55 rmining patient susceptibility to developing adverse drug reactions, although the underlying mechanis

56 lar mechanism of undesirable drug effects or adverse drug reactions among those compounds, we examine

57 iate stage) between the identification of an adverse drug reaction and the subsequent onset of drug-i

58 Thiopurine-related adverse drug reactions and thiopurine failure are freque

59 ams was used to assess treatment completion, adverse drug reactions, and factors associated with trea

60 promiscuous drugs, polypharmacology-related adverse drug reactions, and multi-drug therapies, especi

61 Adverse drug reactions are a frequent culprit.

62 Adverse drug reactions are a significant cause of morbid

63 Adverse drug reactions are a significant public health p

64 Although many adverse drug reactions are considered nonpreventable, re

65 Schemes for spontaneous reporting of adverse drug reactions are important to post-marketing s

66 Idiosyncratic adverse drug reactions are unpredictable, dose-independe

67 ed approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to opti

68 Three adverse drug reaction assessment instruments were used t

69 objective was to determine the prevalence of adverse drug reactions associated with off-label use and

70 e, indicating that doctors should report all adverse drug reactions associated with them to the Commi

71 e phenotypes can range from life-threatening adverse drugs reactions at one end of the spectrum to eq

72 with acute adenovirus infections or systemic adverse drug reactions, but levels in patients with KD w

73 s seldom studied in other types of cutaneous adverse drug reactions (cADRs).

74 in-induced thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directe

75 istered and the number of harmful and severe adverse drug reactions did not differ for medications us

76 Although adverse drug reactions do not occur more frequently with

77 s (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or

78 Tremor rates and adverse drug reactions favoured the placebo group.

79 the evidence for a genetic predisposition to adverse drug reactions, focusing on gene variants produc

80 The number of adverse drug reactions for medications administered and

81 ded demographics, costs, outcomes (including adverse drug reactions, functional status, ventilator ti

82 vate platelets, leading to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (

83 e Abs are associated with an immune-mediated adverse drug reaction, heparin-induced thrombocytopenia.

84 nsight into the molecular mechanisms of this adverse drug reaction in adult patients with germ cell t

85 vs 23/27; P = .0001), with no recurrence of adverse drug reactions in 74%.

86 use as a risk factor for the development of adverse drug reactions in an adult ICU population.

87 present a novel method to better investigate adverse drug reactions in chemical space.

88 Adverse drug reactions in children are an important publ

89 drug testing does not predict some forms of adverse drug reactions in humans.

90 urveillance techniques to reduce the risk of adverse drug reactions in patients receiving warfarin.

91 extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous

92 control group) or amiodarone side effects or adverse drug reactions (in the rhythm-control group).

93 c transporter genes previously implicated in adverse drug reactions including simvastatin-induced myo

94 Adverse drug reactions, including severe patient bleedin

95 It was found that the rate of adverse drug reactions increases by 8% for every one add

96 Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction involving extensive keratinocyte d

97 ng the unintended 'off-targets' that predict adverse drug reactions is daunting by empirical methods

98 their unintended 'off-targets' that predict adverse drug reactions, is a daunting task by experiment

99 ne-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and cau

100 ion in renal transplant recipients, reported adverse drug reactions may limit use and increase relian

101 an explanation for HLA-linked idiosyncratic adverse drug reactions, namely that drugs can alter the

102 rget of a given drug, creating a drug-target-adverse drug reaction network.

103 ulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated i

104 Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction occurring in up to 5% of patients

105 a (HIT) is a relatively common prothrombotic adverse drug reaction of unusual pathogenesis that featu

106 By integrating data sources about adverse drug reactions of drugs with an established chem

107 Drug-induced taste disturbance is a common adverse drug reaction often triggered by drug secretion

108 Secondary outcomes included adverse drug reaction, PICC line complication, and a com

109 drug acquisition cost, and costs of treating adverse drug reactions probably or possibly related to s

110 Three subjects reported mild adverse drug reactions related to FCM; two of these were

111 Our institutional adverse drug reaction reporting program was used to iden

112 were used to determine the probability of an adverse drug reaction resulting from drug therapy.

113 centrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharma

114 iomarkers with the strongest associations to adverse drug reaction risk in the intensive care unit ar

115 ot occur more frequently with off-label use, adverse drug reaction risk increases with each additiona

116 re subsequently discovered to have suspected adverse drug reactions (SADRs).

117 Adverse drug reaction screens in a kidney panel revealed

118 While recent advances in pharmacogenetics of adverse drug reactions show promise, the small size of t

119 s recent literature documenting the risk for adverse drug reactions specific to bleeding and/or clott

120 We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allel

121 reciation of the role that genetics plays in adverse drug reactions that are either predictable exten

122 objective of pharmacovigilance is to detect adverse drug reactions that are unknown or novel in term

123 ylactoid reactions are common clinical acute adverse drug reactions that can exacerbate a patient's c

124 The role of the adaptive immune system in adverse drug reactions that target the liver has not bee

125 rld Health Organization's classification for adverse drug reactions, the association between bortezom

126 In an effort to prevent adverse drug reactions, the FDA mandates the evaluation

127 ere assessed daily for the development of an adverse drug reaction through active surveillance.

128 tcome was any clinical event described as an adverse drug reaction to one or more drugs.

129 potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less

130 anges in cholesterol levels that could cause adverse drug reactions to cholesterol-lowering drugs suc

131 allele that may be associated with the rare adverse drug reaction torsades de pointes.

132 Severity and harm of the adverse drug reaction were also assessed.

133 Rates of adverse drug reaction were low (<4% in both groups) but

134 One hundred and sixteen adverse drug reactions were categorized dichotomously (F

135 The incidence and severity of other adverse drug reactions were comparable between the 2 gro

136 Adverse drug reactions were less common in the TMP-SMX p

137 Discontinuations due to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%

138 The most common adverse drug reactions were ocular side effects, includi

139 Three adverse drug reactions were regarded as both serious and

140 Adverse drug reactions were reported by 1174 (35.7%) pat

141 53% (27) of 51 events classified as serious adverse drug reactions were reported.

142 severe, but no suspected unexpected serious adverse drug reactions were seen.

143 taphylococcus aureus sinusitis, and multiple adverse drug reactions whose T cells were unable to prod

144 ion of genetic variants associated with this adverse drug reaction will further our mechanistic under

145 Less than 1% of women reported adverse drug reactions, with no increase in HIV-positive